AGTR1 and COVID-19: Following this line of evidence, by enhancing ACE2 expression [35,36,37,38] and limiting the effects of unopposed angiotensin II on the heart, lungs, kidney, and vasculature, RAS-modifiers (and especially ARBs acting distally in the RAS to block the angiotensin II type 1 receptor selectively, Figure 4) have the potential to exert a better protective role in patients with COVID-19 when compared with other BP-lowering drugs [2,3,4,39,40,41,42,43,44,45].